Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine

Benjamin W. Friedman, Eddie Irizarry, Clemencia Solorzano, Alexander Latev, Karolyn Rosa, Eleftheria Zias, David R. Vinson, Polly E. Bijur, E. John Gallagher

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

OBJECTIVE: To determine outcomes among patients with migraine in the emergency department (ED) who receive IV hydromorphone vs IV prochlorperazine + diphenhydramine.

METHODS: This study was conducted in 2 EDs in New York City. Patients who met international criteria for migraine were eligible for participation if they had not used an opioid within the previous month. Clinicians, participants, investigators, and research personnel were blinded to treatment. Patients were randomized in blocks of 4. Participants received hydromorphone 1 mg or prochlorperazine 10 mg + diphenhydramine 25 mg. Diphenhydramine was administered to prevent akathisia, a common side effect of IV prochlorperazine. The primary outcome was sustained headache relief, defined as achieving a headache level of mild or none within 2 hours of medication administration and maintaining that level for 48 hours without the requirement of rescue medication. A planned interim analysis was conducted once 48-hour data were available for 120 patients.

RESULTS: The trial was halted by the data monitoring committee after 127 patients had been enrolled. The primary outcome was achieved in the prochlorperazine arm by 37 of 62 (60%) participants and in the hydromorphone arm by 20 of 64 (31%) participants (difference 28%, 95% confidence interval 12-45, number needed to treat 4, 95% confidence interval 2-9).

CONCLUSIONS: IV hydromorphone is substantially less effective than IV prochlorperazine for the treatment of acute migraine in the ED and should not be used as first-line therapy.

CLINICALTRIALSGOV IDENTIFIER: NCT02389829.

CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients in the ED with migraine, IV prochlorperazine + diphenhydramine is superior to IV hydromorphone.

Original languageEnglish (US)
Pages (from-to)2075-2082
Number of pages8
JournalNeurology
Volume89
Issue number20
DOIs
StatePublished - Nov 14 2017

Fingerprint

Prochlorperazine
Hydromorphone
Diphenhydramine
Migraine Disorders
Hospital Emergency Service
Headache
Clinical Trials Data Monitoring Committees
Research Personnel
Confidence Intervals
Numbers Needed To Treat
Psychomotor Agitation
Opioid Analgesics
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. / Friedman, Benjamin W.; Irizarry, Eddie; Solorzano, Clemencia; Latev, Alexander; Rosa, Karolyn; Zias, Eleftheria; Vinson, David R.; Bijur, Polly E.; Gallagher, E. John.

In: Neurology, Vol. 89, No. 20, 14.11.2017, p. 2075-2082.

Research output: Contribution to journalArticle

Friedman, Benjamin W. ; Irizarry, Eddie ; Solorzano, Clemencia ; Latev, Alexander ; Rosa, Karolyn ; Zias, Eleftheria ; Vinson, David R. ; Bijur, Polly E. ; Gallagher, E. John. / Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. In: Neurology. 2017 ; Vol. 89, No. 20. pp. 2075-2082.
@article{614839bd8a4f42289ab71fa9efc76f04,
title = "Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine",
abstract = "OBJECTIVE: To determine outcomes among patients with migraine in the emergency department (ED) who receive IV hydromorphone vs IV prochlorperazine + diphenhydramine.METHODS: This study was conducted in 2 EDs in New York City. Patients who met international criteria for migraine were eligible for participation if they had not used an opioid within the previous month. Clinicians, participants, investigators, and research personnel were blinded to treatment. Patients were randomized in blocks of 4. Participants received hydromorphone 1 mg or prochlorperazine 10 mg + diphenhydramine 25 mg. Diphenhydramine was administered to prevent akathisia, a common side effect of IV prochlorperazine. The primary outcome was sustained headache relief, defined as achieving a headache level of mild or none within 2 hours of medication administration and maintaining that level for 48 hours without the requirement of rescue medication. A planned interim analysis was conducted once 48-hour data were available for 120 patients.RESULTS: The trial was halted by the data monitoring committee after 127 patients had been enrolled. The primary outcome was achieved in the prochlorperazine arm by 37 of 62 (60{\%}) participants and in the hydromorphone arm by 20 of 64 (31{\%}) participants (difference 28{\%}, 95{\%} confidence interval 12-45, number needed to treat 4, 95{\%} confidence interval 2-9).CONCLUSIONS: IV hydromorphone is substantially less effective than IV prochlorperazine for the treatment of acute migraine in the ED and should not be used as first-line therapy.CLINICALTRIALSGOV IDENTIFIER: NCT02389829.CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients in the ED with migraine, IV prochlorperazine + diphenhydramine is superior to IV hydromorphone.",
author = "Friedman, {Benjamin W.} and Eddie Irizarry and Clemencia Solorzano and Alexander Latev and Karolyn Rosa and Eleftheria Zias and Vinson, {David R.} and Bijur, {Polly E.} and Gallagher, {E. John}",
year = "2017",
month = "11",
day = "14",
doi = "10.1212/WNL.0000000000004642",
language = "English (US)",
volume = "89",
pages = "2075--2082",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "20",

}

TY - JOUR

T1 - Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine

AU - Friedman, Benjamin W.

AU - Irizarry, Eddie

AU - Solorzano, Clemencia

AU - Latev, Alexander

AU - Rosa, Karolyn

AU - Zias, Eleftheria

AU - Vinson, David R.

AU - Bijur, Polly E.

AU - Gallagher, E. John

PY - 2017/11/14

Y1 - 2017/11/14

N2 - OBJECTIVE: To determine outcomes among patients with migraine in the emergency department (ED) who receive IV hydromorphone vs IV prochlorperazine + diphenhydramine.METHODS: This study was conducted in 2 EDs in New York City. Patients who met international criteria for migraine were eligible for participation if they had not used an opioid within the previous month. Clinicians, participants, investigators, and research personnel were blinded to treatment. Patients were randomized in blocks of 4. Participants received hydromorphone 1 mg or prochlorperazine 10 mg + diphenhydramine 25 mg. Diphenhydramine was administered to prevent akathisia, a common side effect of IV prochlorperazine. The primary outcome was sustained headache relief, defined as achieving a headache level of mild or none within 2 hours of medication administration and maintaining that level for 48 hours without the requirement of rescue medication. A planned interim analysis was conducted once 48-hour data were available for 120 patients.RESULTS: The trial was halted by the data monitoring committee after 127 patients had been enrolled. The primary outcome was achieved in the prochlorperazine arm by 37 of 62 (60%) participants and in the hydromorphone arm by 20 of 64 (31%) participants (difference 28%, 95% confidence interval 12-45, number needed to treat 4, 95% confidence interval 2-9).CONCLUSIONS: IV hydromorphone is substantially less effective than IV prochlorperazine for the treatment of acute migraine in the ED and should not be used as first-line therapy.CLINICALTRIALSGOV IDENTIFIER: NCT02389829.CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients in the ED with migraine, IV prochlorperazine + diphenhydramine is superior to IV hydromorphone.

AB - OBJECTIVE: To determine outcomes among patients with migraine in the emergency department (ED) who receive IV hydromorphone vs IV prochlorperazine + diphenhydramine.METHODS: This study was conducted in 2 EDs in New York City. Patients who met international criteria for migraine were eligible for participation if they had not used an opioid within the previous month. Clinicians, participants, investigators, and research personnel were blinded to treatment. Patients were randomized in blocks of 4. Participants received hydromorphone 1 mg or prochlorperazine 10 mg + diphenhydramine 25 mg. Diphenhydramine was administered to prevent akathisia, a common side effect of IV prochlorperazine. The primary outcome was sustained headache relief, defined as achieving a headache level of mild or none within 2 hours of medication administration and maintaining that level for 48 hours without the requirement of rescue medication. A planned interim analysis was conducted once 48-hour data were available for 120 patients.RESULTS: The trial was halted by the data monitoring committee after 127 patients had been enrolled. The primary outcome was achieved in the prochlorperazine arm by 37 of 62 (60%) participants and in the hydromorphone arm by 20 of 64 (31%) participants (difference 28%, 95% confidence interval 12-45, number needed to treat 4, 95% confidence interval 2-9).CONCLUSIONS: IV hydromorphone is substantially less effective than IV prochlorperazine for the treatment of acute migraine in the ED and should not be used as first-line therapy.CLINICALTRIALSGOV IDENTIFIER: NCT02389829.CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients in the ED with migraine, IV prochlorperazine + diphenhydramine is superior to IV hydromorphone.

UR - http://www.scopus.com/inward/record.url?scp=85037689485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037689485&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000004642

DO - 10.1212/WNL.0000000000004642

M3 - Article

C2 - 29046364

AN - SCOPUS:85037689485

VL - 89

SP - 2075

EP - 2082

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 20

ER -